Announcement on behalf of Amaran of resolution to lift the non-competition restrictions for new directors
2024.May.29
Announcement on behalf of Amaran of important resolutions at the 2024 Annual General Shareholders’ meeting.
2024.May.10
OBI announces the termination of license agreement with Odeon for the rights of OBI-999 and OBI-833 in China, Hong Kong and Macau
2024.May.10
Announcement of the Consolidated Financial Statements for the first quarter of 2024 were approved by the Board of Directors.
2024.May.10
Correct consolidated financial reports from 2023Q1 to Q4, independent 2024Q4 financial report, and iXBRL, which have no impact on income and losses and net assets.
2024.May.02
Announcement on behalf of OBIGEN that TFDA clears OBI-858’s IND application for Phase II human clinical trial
2024.Apr.25
Announcement of the Company’s board meeting date to approve 2024Q1 consolidated financial report
2024.Apr.12
Announcement on behalf of Amaran of not Distributing Dividends of 2023
2024.Apr.12
Announcement on behalf of Amaran that the BOD resolved to convene the 2024 Annual General Shareholders' Meeting
2024.Mar.20
Announcement on behalf of OBIGEN of not Distributing Dividends of 2023
